A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, RosiƱol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG
Br J Haematol. 2017 178 (4): 547-560

PMID: 28466536 · PMCID: PMC6812508 · DOI:10.1111/bjh.14708

MeSH Terms (13)

Antineoplastic Agents Benchmarking Bortezomib Cardiovascular Diseases Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Dyspnea Heart Failure Humans Multiple Myeloma Proteasome Inhibitors Retrospective Studies Risk Factors

Connections (1)

This publication is referenced by other Labnodes entities: